Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | MYC | P01106 | 1/20 | 0.32 |
| ▸ | ALDH2 | P05091 | 1/20 | 0.32 |
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.32 |
| ▸ | SELL | P14151 | 1/20 | 0.32 |
| ▸ | SELP | P16109 | 1/20 | 0.32 |
| ▸ | SELE | P16581 | 1/20 | 0.32 |
| ▸ | ACHE | P22303 | 1/20 | 0.32 |
| ▸ | KDM1A | O60341 | 2/20 | 0.31 |
| ▸ | KDM1B | Q8NB78 | 1/20 | 0.31 |
| ▸ | RAPGEF4 | Q8WZA2 | 2/20 | 0.31 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5778579 | 0.80 | ACHE (0.40) | ALDH1A1MYCALDH2ALDH3A1SELL | |
| SCHEMBL30668 | 0.80 | HDAC1 (0.48) | HDAC1HDAC6ALDH1A1SELLSELP | |
| SCHEMBL4602927 | 0.79 | AGTR1 (0.40) | HDAC1HDAC6ALDH1A1KDM1AKDM1B | |
| SCHEMBL27213046 | 0.79 | AKR1B1 (0.36) | HDAC1HDAC6ALDH1A1MYCALDH2 | |
| SCHEMBL28872076 | 0.79 | CYP3A4 (0.38) | HDAC1HDAC6ALDH1A1KDM1AKDM1B | |
| SCHEMBL22102332 | 0.79 | RAPGEF4 (0.39) | HDAC1HDAC6ALDH1A1MYCALDH2 | |
| SCHEMBL12689887 | 0.76 | HDAC1 (0.37) | HDAC1HDAC6ALDH1A1KDM1AKDM1B | |
| SCHEMBL23927494 | 0.75 | ALOX5 (0.39) | HDAC1HDAC6ALDH1A1 | |
| SCHEMBL8389021 | 0.75 | GAA (0.46) | HDAC1HDAC6ALDH1A1KDM1AKDM1B | |
| SCHEMBL17252791 | 0.75 | MYC (0.31) | ALDH1A1MYCALDH2ALDH3A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12065399-B2 | Arylsulfonamide derivatives | HOFFMANN-LA ROCHE INC. (US) | 2024-08-20 | — | — | US | disclosed |
| US-11877511-B2 | Materials for organic light emitting devices | MERCK PATENT GMBH (DE) | 2024-01-16 | — | — | US | disclosed |
| EP-4013495-B1 | ARYLSULFONAMIDE DERIVATIVES AS MGLUR4 NEGATIVE ALLOSTERIC MODULATORS | HOFFMANN LA ROCHE (CH) | 2023-09-27 | — | — | EP | disclosed |
| EP-4013495-B1 | ARYLSULFONAMIDE DERIVATIVES AS MGLUR4 NEGATIVE ALLOSTERIC MODULATORS | HOFFMANN LA ROCHE (CH) | 2023-09-27 | — | — | EP | disclosed |
| US-20230125939-A1 | MATERIALS FOR ORGANIC LIGHT EMITTING DEVICES | MERCK PATENT GMBH (DE) | 2023-04-27 | — | — | US | disclosed |
| EP-3368520-B1 | MATERIALS FOR ORGANIC ELECTROLUMINESCENT DEVICES | MERCK PATENT GMBH (DE) | 2023-04-26 | — | — | EP | disclosed |
| EP-4013495-A1 | ARYLSULFONAMIDE DERIVATIVES AS MGLUR4 NEGATIVE ALLOSTERIC MODULATORS | F. Hoffmann-La Roche AG (CH) | 2022-06-22 | — | — | EP | disclosed |
| US-11355714-B2 | Materials for organic electroluminescent devices | MERCK PATENT GMBH (DE) | 2022-06-07 | — | — | US | disclosed |
| US-20220169599-A1 | ARYLSULFONAMIDE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2022-06-02 | — | — | US | disclosed |
| US-20220169599-A1 | ARYLSULFONAMIDE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2022-06-02 | — | — | US | disclosed |
| US-20100234350-A1 | PLATELET ADP RECEPTOR INHIBITORS | PORTOLA PHARMACEUTICALS, INC. (US) | 2010-09-16 | — | — | US | disclosed |
| US-20100234350-A1 | PLATELET ADP RECEPTOR INHIBITORS | PORTOLA PHARMACEUTICALS, INC. (US) | 2010-09-16 | — | — | US | disclosed |
| US-7622474-B2 | Asulfonyl(urea, thiourea, guanidine, cyanoguanidine) compounds; cardiovascular disorders; thrombosis | PORTOLA PHARMACEUTICALS, INC. (US) | 2009-11-24 | — | — | US | disclosed |
| US-7622474-B2 | Asulfonyl(urea, thiourea, guanidine, cyanoguanidine) compounds; cardiovascular disorders; thrombosis | PORTOLA PHARMACEUTICALS, INC. (US) | 2009-11-24 | — | — | US | disclosed |
| US-7435455-B2 | Dihydrocoumarin derivative, liquid crystal composition containing the same, and liquid crystal display device | CHISSO CORPORATION (JP) | 2008-10-14 | — | — | US | disclosed |
| US-20080194597-A1 | Asulfonyl(urea, thiourea, guanidine, cyanoguanidine) compounds; cardiovascular disorders; thrombosis | PORTOLA PHARMACEUTICALS, INC. (US) | 2008-08-14 | — | — | US | disclosed |
| US-20080194597-A1 | Asulfonyl(urea, thiourea, guanidine, cyanoguanidine) compounds; cardiovascular disorders; thrombosis | PORTOLA PHARMACEUTICALS, INC. (US) | 2008-08-14 | — | — | US | disclosed |
| US-7358257-B2 | sulfonylurea derivatives, sulfonylthiourea derivatives, sulfonylguanidine derivatives, sulfonylcyanoguanidine derivatives, thioacylsulfonamide derivatives, and acylsulfonamide derivatives; effective for prevention and treatment of cardiovascular diseases, antithrombotic agents | PORTOLA PHARMACEUTICALS, INC. (US) | 2008-04-15 | — | — | US | disclosed |
| US-7358257-B2 | sulfonylurea derivatives, sulfonylthiourea derivatives, sulfonylguanidine derivatives, sulfonylcyanoguanidine derivatives, thioacylsulfonamide derivatives, and acylsulfonamide derivatives; effective for prevention and treatment of cardiovascular diseases, antithrombotic agents | PORTOLA PHARMACEUTICALS, INC. (US) | 2008-04-15 | — | — | US | disclosed |
| EP-0113185-A1 | Selective bromination process | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1984-07-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230125939-A1 | MATERIALS FOR ORGANIC LIGHT EMITTING DEVICES | DDT, ESD, ETFA | HDAC1 3304/4885HDAC6 2718/4885ALDH1A1 389/4885 |
| US-20100234350-A1 | PLATELET ADP RECEPTOR INHIBITORS | TBXA2R, GP6, P2RY6 | HDAC1 3146/4885HDAC6 1263/4885ALDH1A1 1369/4885 |
| US-20080194597-A1 | Asulfonyl(urea, thiourea, guanidine, cyanoguanidine) compounds; cardiovascular disorders; thrombosis | PIGS, GP6, ASGR1 | HDAC1 2831/4885HDAC6 1406/4885ALDH1A1 1520/4885 |
| US-11355714-B2 | Materials for organic electroluminescent devices | SLCO4C1, SLCO2A1, SLCO2B1 | HDAC1 2807/4885HDAC6 3949/4885ALDH1A1 1315/4885 |
| US-11877511-B2 | Materials for organic light emitting devices | DDT, ESD, ETFA | HDAC1 3304/4885HDAC6 2718/4885ALDH1A1 389/4885 |
| US-20220169599-A1 | ARYLSULFONAMIDE DERIVATIVES | ARSA, SULT1E1, STS | HDAC1 872/4885HDAC6 759/4885ALDH1A1 378/4885 |
| US-12065399-B2 | Arylsulfonamide derivatives | ARSA, SULT1E1, STS | HDAC1 872/4885HDAC6 759/4885ALDH1A1 378/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.